Missak Haigentz - Concepedia

Author

Missak Haigentz

Albert Einstein College of Medicine ORCID

Also Known As

Carl E. Silver, Haigentz, M., Leon, Marino E., M. Haigentz, M. Haigentz Jr, Missak Haigentz, Missak Haigentz Jr, S. Anai

222

Publications

Citations

H-Index

Concepts

All Affiliations

Albert Einstein College of Medicine Montefiore Medical Center Yeshiva University Johns Hopkins University Emory University

About

Missak Haigentz is an author at Albert Einstein College of Medicine specializing in oncology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	24	1.5K
2	Health Sciences	3	3	94
3	Natural Sciences	1	1	15
4	Biochemistry	1	1	15
5	Biostatistics	1	1	15

Missak Haigentz

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Athanassios Argiris, Shuli Li, P. Savvides, Journal of Clinical Oncology	2019	117
Salivary mucoepidermoid carcinoma revisited Andrés Coca‐Pelaz, Juan P. Rodrigo, Asterios Triantafyllou, European Archives of Oto-Rhino-Laryngology MedicineOral CavityOral BiologyPathologySalivary Gland	2014	99
Tracheostomy during <scp>SARS‐CoV</scp>‐2 pandemic: Recommendations from the New York Head and Neck Society Brett A. Miles, Bradley A. Schiff, Ian Ganly, Head & Neck	2020	98
Combined P16 and human papillomavirus testing predicts head and neck cancer survival Christian R. Salazar, Nicole Anayannis, Richard V. Smith, International Journal of Cancer	2014	96
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer Missak Haigentz, Mimi Kim, Catherine Sarta, Oral Oncology Neck CancerOncologyPhase Ii TrialMedicineRecurrent/metastatic Head	2012	90
Current trends in initial management of oropharyngeal cancer: the declining use of open surgery Missak Haigentz, Carl E. Silver, June Corry, European Archives of Oto-Rhino-Laryngology Surgical OncologyMedicineCancer ManagementInitial ManagementOpen Surgery	2009	73
RETRACTION: Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27 Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines Yi‐He Ling, Tianhong Li, Ziqiang Yuan, Molecular Pharmacology	2007	72
Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Survival: A Comparison by Tumor Site and Initial Treatment Christian R. Salazar, Richard V. Smith, Madhur Garg, Head and Neck Pathology Human Papillomavirus-associated HeadHuman Papillomavirus VaccinesInitial TreatmentMedicineNasopharyngeal Cancer	2013	68
The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients Richard V. Smith, Bradley A. Schiff, Madhur Garg, The Laryngoscope	2015	66

Page 1